| Title： | Emergency experts consensus on clinical application of Ulinastatin |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | Clinician |
| Evidence classification method： | Grade classification is preliminarily considered |
| Development unit： | the Second Affiliated Hospital of Xi'an Jiaotong University |
| Registration time: | 2022-07-13 |
| Registration number： | IPGRP-2022CN400 |
| Purpose of the guideline: | Ulinastatin is a serine protease inhibitor with anti-inflammatory effect. Its application value in shock, sepsis, acute respiratory distress syndrome, burns and other diseases has been clinically recognized, and has been recommended by many experts consensus or guidelines. However, due to the lack of unified clinical application guidelines or specifications around Ulinastatin, it is not convenient for clinicians to use it in practical work. In order to regulate the rational application of ulinastatin in the field of acute, critical and severe diseases, it is proposed to formulate the "Emergency experts consensus on clinical application of Ulinastatin". |
Latest registration
